Novo Nordisk slides as investors digest FDA warning letter tied to semaglutide safety reporting

Novo Nordisk A/S (NVO) is down 3.6% today. Here is some analysis on what might have caused this price movement.

Analysis: The most likely driver is renewed investor concern around a recent FDA warning letter focused on Novo Nordisk’s pharmacovigilance processes for semaglutide products (a key franchise for the company). With the stock already sensitive to regulatory and competitive headlines, the letter may have amplified worries about potential remediation costs, heightened scrutiny, or distractions for management.

Details:

The FDA published a warning letter dated March 5, 2026, describing deficiencies tied to adverse drug experience reporting processes at Novo Nordisk’s U.S. organization.

The issues referenced relate to semaglutide, the active ingredient used in major products such as Ozempic and Wegovy, which are central to Novo Nordisk’s growth narrative.

The letter discusses corrective actions and procedural updates Novo Nordisk described, but the existence of the warning can still be viewed as a negative signal for compliance risk and regulator attention.

This pullback may also reflect broader, lingering caution after the company’s recent messaging that 2026 could be a tougher year commercially, making the market less willing to “look through” new headlines.

Sources:

U.S. Food and Drug Administration, Novo Nordisk (Investor Relations), Yahoo News

Disclaimer: This price movement analysis was generated with the help of AI. Please double-check the information provided for mistakes.

$NVO Hedge Fund Activity

We have seen 592 institutional investors add shares of $NVO stock to their portfolio, and 976 decrease their positions in their most recent quarter.

Here are some of the largest recent moves:

KINGSTONE CAPITAL PARTNERS TEXAS, LLC removed 10,005,216 shares (-100.0%) from their portfolio in Q3 2025, for an estimated $555,189,435
CAPITAL INTERNATIONAL INVESTORS removed 6,502,318 shares (-36.7%) from their portfolio in Q4 2025, for an estimated $330,837,939
PRICE T ROWE ASSOCIATES INC /MD/ added 4,836,285 shares (+99.7%) to their portfolio in Q4 2025, for an estimated $246,070,180
VOLORIDGE INVESTMENT MANAGEMENT, LLC added 4,302,126 shares (+851.6%) to their portfolio in Q4 2025, for an estimated $218,892,170
CITADEL ADVISORS LLC added 4,278,889 shares (+136.6%) to their portfolio in Q4 2025, for an estimated $217,709,872
GOLDMAN SACHS GROUP INC added 4,270,420 shares (+63.6%) to their portfolio in Q4 2025, for an estimated $217,278,969
FMR LLC removed 4,058,066 shares (-28.8%) from their portfolio in Q4 2025, for an estimated $206,474,398

To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.

$NVO Congressional Stock Trading

Members of Congress have traded $NVO stock 4 times in the past 6 months. Of those trades, 2 have been purchases and 2 have been sales.

Here’s a breakdown of recent trading of $NVO stock by members of Congress over the last 6 months:

REPRESENTATIVE LISA C. MCCLAIN has traded it 3 times. They made 1 purchase worth up to $15,000 on 10/30 and 2 sales worth up to $30,000 on 10/31, 10/30.
REPRESENTATIVE MARJORIE TAYLOR GREENE purchased up to $15,000 on 10/15.

To track congressional stock trading, check out Quiver Quantitative's congressional trading dashboard.

$NVO Analyst Ratings

Wall Street analysts have issued reports on $NVO in the last several months. We have seen 1 firms issue buy ratings on the stock, and 2 firms issue sell ratings.

Here are some recent analyst ratings:

Goldman Sachs issued a "Buy" rating on 11/28/2025
Jefferies issued a "Underperform" rating on 10/27/2025
Morgan Stanley issued a "Underweight" rating on 09/29/2025

To track analyst ratings and price targets for $NVO, check out Quiver Quantitative's $NVO forecast page.

$NVO Price Targets

Multiple analysts have issued price targets for $NVO recently. We have seen 5 analysts offer price targets for $NVO in the last 6 months, with a median target of $47.0.

Here are some recent targets:

James Quigley from Goldman Sachs set a target price of $41.0 on 03/02/2026
An analyst from CICC set a target price of $73.5 on 01/09/2026
Evan David Seigerman from BMO Capital set a target price of $46.0 on 11/25/2025
Rajesh Kumar from HSBC set a target price of $70.0 on 10/02/2025
Thibault Boutherin from Morgan Stanley set a target price of $47.0 on 09/29/2025

This article is not financial advice. See Quiver Quantitative's disclaimers for more information. Note that there may be inaccuracies due to mistakes in ticker-mapping, and other anomalies.